CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eiger Biopharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eiger Biopharmaceuticals Inc
2155 Park Blvd
Phone: (650) 279-9845p:650 279-9845 PALO ALTO, CA  94306-1543  United States Fax: (650) 618-1621f:650 618-1621
This company's Plan of Liquidation went into effect on 9/30/2024
This company ceased filing statements with the SEC on 10/1/2024.
This company is no longer actively traded on any major stock exchange.
Business Summary
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes--

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Thomas J.Dietz 60 1/1/2019 3/22/2016
Chief Executive Officer, Director DavidApelian 59 6/28/2023 6/14/2017
Chief Compliance Officer, General Counsel, Corporate Secretary James A.Vollins 55 4/1/2023 4/1/2023
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
EigerBio Europe Limited Room 002, 28-32 Pembroke Street Upper Dublin Ireland
EBPI Merger Inc. 2155 Park Boulevard Palo Alto CA United States

Business Names
Business Name
EB Pharma LLC
EB Pharma LLC
EBPI Merger Inc.
8 additional Business Names available in full report.

General Information
Outstanding Shares: 1,480,797 (As of 4/24/2024)
Shareholders: 17
Stock Exchange: OTC
Federal Tax Id: 330971591
Fax Number: (650) 618-1621


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024